SCHEMBL23925667

SCHEMBL23925667

COc1ccc(CNc2cc(C(=O)O)ncn2)c(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 13/20 0.60
CYP3A4 P08684 13/20 0.60
CYP2D6 P10635 12/20 0.60
CYP2C19 P33261 11/20 0.60
TSHR P16473 11/20 0.60
CLK4 Q9HAZ1 9/20 0.60
ALDH1A1 P00352 6/20 0.60
USP2 O75604 6/20 0.60
MAPK1 P28482 4/20 0.60
LMNA P02545 4/20 0.60
HSD17B10 Q99714 2/20 0.60
ALOX15 P16050 1/20 0.60
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
GLA P06280 1/20 0.57
KDM4C Q9H3R0 1/20 0.55
MAPT P10636 1/20 0.54
CYP2C9 P11712 1/20 0.53
NPSR1 Q6W5P4 1/20 0.50
APLNR P35414 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17149372 0.81 KDM4C (0.53) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL30711679 0.81 CYP1A2 (0.67) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL20237993 0.81 CYP1A2 (0.67) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL28091678 0.81 CYP1A2 (0.58) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL16343541 0.81 KDM4C (0.64) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL31042791 0.81 KDM4C (0.60) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL28320773 0.81 KDM4C (0.60) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL1690631 0.80 CYP1A2 (0.68) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL31275112 0.79 KDM4C (0.57) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL21174364 0.78 KDM4C (0.52) CYP1A2CYP3A4CYP2D6CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295119-A1 SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES GOSSAMER BIO SERVICES INC (US) 2023-09-21 US disclosed
EP-4136073-A1 SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES Gossamer Bio Services, Inc. (US) 2023-02-22 EP disclosed
CN-115702145-A Substituted pyridines for the treatment of inflammatory diseases 戈萨默生物服务公司 2023-02-14 CN disclosed
WO-2021211741-A1 SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES GOSSAMER BIO SERVICES, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295119-A1 SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES IRAK3, TYK2, IRAK2 CYP1A2 490/4885CYP3A4 1364/4885CYP2D6 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.